EA202092589A3 - Cxcr2-связывающие полипептиды - Google Patents
Cxcr2-связывающие полипептидыInfo
- Publication number
- EA202092589A3 EA202092589A3 EA202092589A EA202092589A EA202092589A3 EA 202092589 A3 EA202092589 A3 EA 202092589A3 EA 202092589 A EA202092589 A EA 202092589A EA 202092589 A EA202092589 A EA 202092589A EA 202092589 A3 EA202092589 A3 EA 202092589A3
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- polypeptides
- cxcr2
- binding polypeptides
- relates
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Настоящее изобретение относится к полипептидам, направленным против хемокинового рецептора CXCR2 или специфически связывающимся с этим рецептором, в частности к полипептидам, способным модулировать передачу сигнала от CXCR2. Настоящее изобретение также относится к нуклеиновым кислотам, к векторам и к клеткам-хозяевам, способным экспрессировать полипептиды по изобретению, к фармацевтическим композициям, содержащим указанные полипептиды, и к применению указанных полипептидов и композиций для лечения заболеваний, связанных с нарушением функции CXCR2.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41108310P | 2010-11-08 | 2010-11-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
EA202092589A2 EA202092589A2 (ru) | 2021-03-31 |
EA202092589A3 true EA202092589A3 (ru) | 2021-06-30 |
Family
ID=45001722
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202092589A EA202092589A3 (ru) | 2010-11-08 | 2011-11-07 | Cxcr2-связывающие полипептиды |
EA201390666A EA037063B1 (ru) | 2010-11-08 | 2011-11-07 | Cxcr2-связывающие полипептиды |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201390666A EA037063B1 (ru) | 2010-11-08 | 2011-11-07 | Cxcr2-связывающие полипептиды |
Country Status (26)
Country | Link |
---|---|
US (3) | US8591896B2 (ru) |
EP (3) | EP3575321B1 (ru) |
JP (2) | JP5933573B2 (ru) |
KR (2) | KR101832040B1 (ru) |
CN (1) | CN103328512B (ru) |
AR (1) | AR083784A1 (ru) |
AU (4) | AU2011328246B2 (ru) |
BR (1) | BR112013011003B1 (ru) |
CA (1) | CA2817132A1 (ru) |
CL (1) | CL2013001168A1 (ru) |
CO (1) | CO6761351A2 (ru) |
CR (1) | CR20130202A (ru) |
CU (1) | CU24111B1 (ru) |
EA (2) | EA202092589A3 (ru) |
ES (1) | ES2723775T3 (ru) |
GT (1) | GT201300113A (ru) |
IL (1) | IL225897B (ru) |
MA (1) | MA34711B1 (ru) |
MX (2) | MX343085B (ru) |
NZ (1) | NZ610075A (ru) |
PE (1) | PE20140772A1 (ru) |
SG (1) | SG189981A1 (ru) |
TW (2) | TWI619811B (ru) |
UA (1) | UA115027C2 (ru) |
UY (1) | UY33714A (ru) |
WO (1) | WO2012062713A1 (ru) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20140772A1 (es) | 2010-11-08 | 2014-07-03 | Novartis Ag | Polipeptidos que se enlazan a cxcr2 |
US9328174B2 (en) * | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
US20160060347A1 (en) * | 2013-04-17 | 2016-03-03 | Morphosys Ag | Antibodies targeting specifically human cxcr2 |
CN103396482B (zh) * | 2013-05-17 | 2016-08-10 | 东南大学 | 一种前白蛋白纳米抗体、其编码序列及应用 |
US10017559B2 (en) | 2013-11-04 | 2018-07-10 | INSERM (Institut National de la Santé et de la Recherche Médicale | Synthetic single domain antibody |
WO2015189162A1 (en) * | 2014-06-09 | 2015-12-17 | Theranyx | Single-domain antibodies directed against a cys-loop receptor and methods for obtaining them |
EP3471753A1 (en) | 2016-06-20 | 2019-04-24 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
EP3585816A4 (en) | 2017-02-27 | 2020-12-30 | Monash University | CXCR2 ANTIBODIES AND THEIR USES |
US20200277378A1 (en) | 2017-11-16 | 2020-09-03 | Novartis Ag | Combination therapies |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
SG11202100663VA (en) | 2018-08-01 | 2021-02-25 | Cephalon Inc | Anti-cxcr2 antibodies and uses thereof |
CN113271945A (zh) | 2018-12-20 | 2021-08-17 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合 |
JP2022520448A (ja) | 2019-02-15 | 2022-03-30 | ノバルティス アーゲー | 置換3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用 |
WO2020165833A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
CN114787187B (zh) * | 2019-09-04 | 2024-04-16 | 上海科技大学 | 抗cxcr2抗体及其应用 |
CA3165399A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
IL298262A (en) | 2020-06-23 | 2023-01-01 | Novartis Ag | A dosage regimen that includes derivatives of 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione |
EP4188549A1 (en) | 2020-08-03 | 2023-06-07 | Novartis AG | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
US20240068004A1 (en) * | 2022-08-15 | 2024-02-29 | Mbrace Therapeutics, Inc. | Cell-free methods of producing antibodies to intracellular targets |
Family Cites Families (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2052027T5 (es) | 1988-11-11 | 2005-04-16 | Medical Research Council | Clonacion de secuencias de dominio variable de inmunoglobulina. |
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
EP0577752B2 (en) | 1991-03-29 | 2007-07-11 | Genentech, Inc. | Human pf4a receptors and their use |
US5440021A (en) * | 1991-03-29 | 1995-08-08 | Chuntharapai; Anan | Antibodies to human IL-8 type B receptor |
US5374506A (en) | 1991-09-13 | 1994-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Amino acid sequence for a functional human interleukin-8 receptor |
ATE348175T1 (de) | 1992-07-17 | 2007-01-15 | Dana Farber Cancer Inst Inc | Method eder intrazellularen bindung von zielgerichteten molekülen |
PT1498427E (pt) | 1992-08-21 | 2010-03-22 | Univ Bruxelles | Imunoglobulinas desprovidas de cadeias leves |
DK0702721T3 (da) | 1993-06-09 | 2001-05-21 | Unilever Nv | Fremgangsmåde til fremstilling af fusionsproteiner, der omfatter ScFv fragmenter, ved hjælp af en transformeret skimmelsvamp |
US6091639A (en) | 1993-08-27 | 2000-07-18 | Kabushiki Kaisha Toshiba | Non-volatile semiconductor memory device and data programming method |
US6448379B1 (en) | 1993-09-14 | 2002-09-10 | Chiron Corporation | IL8 inhibitors |
WO1995022618A1 (en) | 1994-02-22 | 1995-08-24 | Dana-Farber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
EP1027073A2 (en) | 1996-11-19 | 2000-08-16 | Sangstat Medical Corporation | Enhanced effects for hapten conjugated therapeutics |
US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
DE69841562D1 (de) | 1997-10-27 | 2010-04-29 | Bac Ip Bv | Multivalente antigenbindende proteine |
NZ506453A (en) | 1998-02-19 | 2003-02-28 | Xcyte Therapies Inc | Compositions and methods for regulating lymphocyte activation |
EP0967284A1 (en) | 1998-05-28 | 1999-12-29 | Pfizer Limited | Phosphodiesterases |
GB9824632D0 (en) | 1998-11-10 | 1999-01-06 | Celltech Therapeutics Ltd | Biological compounds |
NZ513356A (en) | 1999-02-05 | 2004-01-30 | Univ Leiden | Method of modulating metabolite biosynthesis in recombinant cells using an AP2-domain transcription factor that is involved in the response of a plant cell to a jasmonate |
US6617122B1 (en) | 1999-03-15 | 2003-09-09 | Xenon Genetics, Inc. | Process for identifying modulators of ABC1 activity |
AR024576A1 (es) | 1999-06-18 | 2002-10-16 | Univ Washington | Composiciones y metodos para aumentar el flujo de salida de colesterol y aumentar la hdl usando la proteina abc1 transportadora del cassette que une elatp |
AU6322900A (en) | 1999-08-02 | 2001-02-19 | Keygene N.V. | Method for generating resistance against cgmmv in plants, genetic constructs for use in said method, and cgmmv-resistant plants obtained via said method |
GB9922124D0 (en) | 1999-09-17 | 1999-11-17 | Pfizer Ltd | Phosphodiesterase enzymes |
DE19955408A1 (de) | 1999-11-18 | 2001-05-23 | Bayer Ag | GABA-B-Rezeptoren |
CA2921260A1 (en) | 1999-12-24 | 2001-06-28 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
AU2001250412A1 (en) * | 2000-03-31 | 2001-10-08 | Ipf Pharmaceuticals Gmbh | Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using specific chemokine receptor analysis and the chemokine receptor-ligand interaction |
AU2001266557A1 (en) | 2000-04-12 | 2001-10-23 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7943129B2 (en) | 2000-05-26 | 2011-05-17 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
US6741957B1 (en) | 2000-07-21 | 2004-05-25 | Daimlerchrysler Corporation | Analytical tire model for vehicle durability and ride comfort analysis |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
EP2706116A1 (en) | 2001-01-17 | 2014-03-12 | Emergent Product Development Seattle, LLC | Binding domain-immunoglobulin fusion proteins |
US7211395B2 (en) | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
JP2004528031A (ja) | 2001-03-14 | 2004-09-16 | セントカー・インコーポレーテツド | 慢性閉塞性肺疾患関連の免疫グロブリン由来タンパク質、組成物、方法および用途 |
GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
JP4303105B2 (ja) | 2001-06-28 | 2009-07-29 | ドマンティス リミテッド | 二重特異性リガンドとその利用 |
US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
EP1425694A2 (en) | 2001-08-03 | 2004-06-09 | Medical Research Council | Method of identifying a consensus sequence for intracellular antibodies |
EP1427829A4 (en) | 2001-08-31 | 2005-10-12 | Abmaxis Inc | MULTIVALENT PROTEIN CONJUGATE WITH SEVERAL LIGANDEN BINDING RECORDORDOMAS |
US7253007B2 (en) | 2001-11-30 | 2007-08-07 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
US7442512B2 (en) * | 2001-11-30 | 2008-10-28 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
KR100599789B1 (ko) | 2001-12-03 | 2006-07-12 | 삼성에스디아이 주식회사 | 방열효율이 향상된 플라즈마 디스플레이 장치 및 그 제조방법 |
CA2471645A1 (en) | 2002-01-03 | 2003-07-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Immunoconjugates useful for treatment of tumours |
JP2006512895A (ja) | 2002-06-28 | 2006-04-20 | ドマンティス リミテッド | リガンド |
US7004940B2 (en) | 2002-10-10 | 2006-02-28 | Ethicon, Inc. | Devices for performing thermal ablation having movable ultrasound transducers |
JP2006512910A (ja) | 2002-10-23 | 2006-04-20 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | A34およびa33様3dna、タンパク質、それらに対する抗体、ならびに同一物を使用した治療方法 |
AU2003284357A1 (en) | 2002-11-01 | 2004-06-07 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
AU2003286004A1 (en) | 2002-11-08 | 2004-06-07 | Ablynx N.V. | Single domain antibodies directed against interferon- gamma and uses therefor |
MXPA05004955A (es) | 2002-11-08 | 2005-11-17 | Ablynx Nv | Anticuerpos de region unica dirigidos contra el factor-alfa de necrosis de tumor y usos de estos. |
GB0228210D0 (en) | 2002-12-03 | 2003-01-08 | Babraham Inst | Single chain antibodies |
CA2507004A1 (en) | 2002-12-03 | 2004-06-17 | Celltech R & D Limited | Assay for identifying antibody producing cells |
NZ541050A (en) | 2002-12-16 | 2010-06-25 | Genmab As | Human monoclonal antibodies against interleukin 8 (IL-8) |
GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
KR101025143B1 (ko) | 2002-12-31 | 2011-04-01 | 넥타르 테라퓨틱스 | 가수분해상으로 안정한 말레이미드-종결 중합체 |
GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
SI1639011T1 (sl) | 2003-06-30 | 2009-04-30 | Domantis Ltd | Pegilirana protitelesa z enojno domeno (dAb) |
CA2535550A1 (en) | 2003-08-12 | 2005-03-03 | William M. Yarbrough | Treatment for acne vulgaris and method of use |
EP1658500B1 (en) | 2003-08-20 | 2012-04-18 | UCB Pharma, S.A. | Methods for obtaining antibodies |
WO2005103702A2 (en) | 2004-04-20 | 2005-11-03 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 2 (cxcr2) |
US20060008601A1 (en) | 2004-06-25 | 2006-01-12 | Zeik Douglas B | Flexible laminate having an integrated pressure release valve |
KR101457753B1 (ko) | 2004-07-22 | 2014-11-03 | 에라스무스 유니버시티 메디컬 센터 로테르담 | 결합 분자 |
US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
US20080107601A1 (en) | 2004-10-13 | 2008-05-08 | Ablynx N.V. | Nanobodies Tm Against Amyloid-Beta and Polypeptides Comprising the Same for the Treatment of Degenerative Neural Diseases Such as Alzheimer's Disease |
WO2006040154A2 (en) | 2004-10-14 | 2006-04-20 | Dublin City University | Prokaryotic two hybrid system |
NO322440B1 (no) | 2004-10-19 | 2006-10-09 | Per-Yngve Monsen | Fremgangsmate og datasystem for ervervelse av kunder |
EP1844073A1 (en) | 2005-01-31 | 2007-10-17 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
MX363423B (es) | 2005-05-18 | 2019-03-22 | Ablynx Nv | Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor. |
CN101213214B (zh) | 2005-05-20 | 2014-06-25 | 埃博灵克斯股份有限公司 | 针对冯威勒布兰特因子的单一结构域vhh抗体 |
EP1910828A4 (en) | 2005-07-01 | 2012-03-14 | Univ St Louis | PHOSPHOSPECTIVE CHEMOKIN RECEPTOR ANTIBODIES |
MY169746A (en) | 2005-08-19 | 2019-05-14 | Abbvie Inc | Dual variable domain immunoglobulin and uses thereof |
WO2007112940A2 (en) | 2006-03-31 | 2007-10-11 | Ablynx N.V. | Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same |
WO2007118670A1 (en) | 2006-04-14 | 2007-10-25 | Ablynx N.V. | Dp-78-like nanobodies |
CN101070346A (zh) * | 2006-05-08 | 2007-11-14 | 陈正贤 | 一种制备双功能抗体的方法 |
EP2040995A1 (en) | 2006-06-26 | 2009-04-01 | Aida Centre, S.L. | Blister package integrating rfid based tags |
US20130004480A1 (en) | 2006-07-04 | 2013-01-03 | Paul Parren | CD20 Binding Molecules for the Treatment of Copd |
JP2010500876A (ja) | 2006-08-18 | 2010-01-14 | アブリンクス エン.ヴェー. | Il−6媒介性シグナル伝達に関連する疾患及び障害の治療のための、il−6rに指向性を有するアミノ酸配列及びこれを含むポリペプチド |
US7943310B2 (en) | 2006-08-30 | 2011-05-17 | Centocor Ortho Biotech Inc. | Methods for assessing response to therapy in subjects having ulcerative colitis |
CA2663042A1 (en) | 2006-09-08 | 2008-03-13 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
JP2010505435A (ja) | 2006-10-11 | 2010-02-25 | アブリンクス エン.ヴェー. | 本質的にpHに非依存的に血清タンパク質に結合するアミノ酸配列、それを含む化合物、およびその使用 |
US20100034194A1 (en) | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
WO2008074839A2 (en) | 2006-12-19 | 2008-06-26 | Ablynx N.V. | Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders |
WO2009138519A1 (en) * | 2008-05-16 | 2009-11-19 | Ablynx Nv | AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME |
CA2712432C (en) | 2008-01-29 | 2018-09-25 | Ablynx N.V. | Methods to stabilize single variable domains |
NL2001374C2 (nl) | 2008-03-13 | 2009-09-15 | Securo B V | Werkwijze voor het machinaal vervaardigen van een samenstel van een eerste flexibel vel en een tweede flexibel vel. |
US9005963B2 (en) | 2008-10-14 | 2015-04-14 | Ablynx N.V. | Amino acid sequences directed against cellular receptors for viruses and bacteria |
CN102257003B (zh) * | 2008-12-19 | 2017-04-05 | 埃博灵克斯股份有限公司 | 用于产生针对细胞相关抗原如p2x7、cxcr7或cxcr4的免疫球蛋白的基因免疫 |
AU2010217120B2 (en) | 2009-02-24 | 2014-11-20 | Novartis Ag | Methods for identifying immunobinders of cell-surface antigens |
PE20140772A1 (es) | 2010-11-08 | 2014-07-03 | Novartis Ag | Polipeptidos que se enlazan a cxcr2 |
-
2011
- 2011-11-07 PE PE2013000967A patent/PE20140772A1/es active IP Right Grant
- 2011-11-07 AR ARP110104148A patent/AR083784A1/es active IP Right Grant
- 2011-11-07 TW TW100140567A patent/TWI619811B/zh active
- 2011-11-07 TW TW105118426A patent/TWI619730B/zh active
- 2011-11-07 JP JP2013537159A patent/JP5933573B2/ja active Active
- 2011-11-07 CA CA2817132A patent/CA2817132A1/en active Pending
- 2011-11-07 CN CN201180064402.2A patent/CN103328512B/zh active Active
- 2011-11-07 KR KR1020157011185A patent/KR101832040B1/ko active IP Right Grant
- 2011-11-07 UA UAA201305197A patent/UA115027C2/uk unknown
- 2011-11-07 EP EP18214738.9A patent/EP3575321B1/en active Active
- 2011-11-07 CU CU20130066A patent/CU24111B1/es active IP Right Grant
- 2011-11-07 BR BR112013011003-1A patent/BR112013011003B1/pt active IP Right Grant
- 2011-11-07 WO PCT/EP2011/069571 patent/WO2012062713A1/en active Application Filing
- 2011-11-07 EP EP11785367.1A patent/EP2638068B1/en active Active
- 2011-11-07 EA EA202092589A patent/EA202092589A3/ru unknown
- 2011-11-07 KR KR1020137014687A patent/KR101650995B1/ko active IP Right Grant
- 2011-11-07 ES ES11785367T patent/ES2723775T3/es active Active
- 2011-11-07 EA EA201390666A patent/EA037063B1/ru unknown
- 2011-11-07 AU AU2011328246A patent/AU2011328246B2/en active Active
- 2011-11-07 SG SG2013031075A patent/SG189981A1/en unknown
- 2011-11-07 MX MX2013005186A patent/MX343085B/es active IP Right Grant
- 2011-11-07 NZ NZ610075A patent/NZ610075A/en not_active IP Right Cessation
- 2011-11-07 US US13/290,175 patent/US8591896B2/en active Active
- 2011-11-07 EP EP19162524.3A patent/EP3578568A3/en active Pending
- 2011-11-08 UY UY0001033714A patent/UY33714A/es not_active Application Discontinuation
-
2013
- 2013-04-22 IL IL225897A patent/IL225897B/en active IP Right Grant
- 2013-04-29 CL CL2013001168A patent/CL2013001168A1/es unknown
- 2013-05-07 GT GT201300113A patent/GT201300113A/es unknown
- 2013-05-08 MX MX2022013520A patent/MX2022013520A/es unknown
- 2013-05-08 CR CR20130202A patent/CR20130202A/es unknown
- 2013-05-24 CO CO13128270A patent/CO6761351A2/es unknown
- 2013-06-05 MA MA35963A patent/MA34711B1/fr unknown
- 2013-10-29 US US14/065,679 patent/US9127067B2/en active Active
-
2015
- 2015-06-26 US US14/751,417 patent/US10174118B2/en active Active
-
2016
- 2016-04-28 JP JP2016091065A patent/JP6294382B2/ja active Active
- 2016-09-28 AU AU2016234907A patent/AU2016234907A1/en not_active Abandoned
-
2018
- 2018-12-03 AU AU2018275016A patent/AU2018275016B2/en active Active
-
2020
- 2020-08-11 AU AU2020217351A patent/AU2020217351B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202092589A3 (ru) | Cxcr2-связывающие полипептиды | |
EA201492048A1 (ru) | Полипептиды, связывающиеся с хемокиновым рецептором | |
MY162737A (en) | 4-1bb binding molecules | |
UA113609C2 (xx) | Антигензв'язуючий білок, який зв'язує людський il-23 | |
PH12015500806B1 (en) | Binding molecules to the human ox40 receptor | |
UA113712C2 (xx) | Антитіло до fap і способи його застосування | |
EA201400964A1 (ru) | Cx3cr1-связывающие полипептиды | |
TN2012000372A1 (en) | Fibronectin based scaffold domain proteins that bind il-23 | |
BR112012025568A2 (pt) | proteínas de ligação ao tnf-<244>. | |
GB201020995D0 (en) | Biological materials and uses thereof | |
EA201590910A1 (ru) | Белки на основе структурного домена фибронектина, связывающие pcsk9 | |
EA201001223A1 (ru) | Стабилизированные белковые композиции | |
MX2011007467A (es) | Dominios modulares de union a dna y metodos de uso. | |
EA201892774A1 (ru) | Антитела | |
EA201690503A1 (ru) | Антитела | |
EA201591898A1 (ru) | Антитела, направленные на m-csf | |
WO2010009227A3 (en) | Recombinant pokeweed antiviral proteins, compositions and methods related thereto | |
TN2013000171A1 (en) | Cxcr2 binding polypeptides | |
WO2009106532A3 (en) | Use of prokaryotic tir-domain containing proteins as therapeutic and diagnostic agents | |
AU2013204150B2 (en) | Modular DNA-binding domains and methods of use |